Navigation Links
Precision Therapeutics Adds 8 Million Covered Lives Under Contract
Date:4/8/2008

PITTSBURGH, April 8, 2008 /PRNewswire/ -- Precision Therapeutics Inc., a leader in personalized medicine, said today it signed contracts with National Preferred Provider Network (NPPN), PlanCare America (PCA), RMSCO, and SEIBA Inc.

NPPN, headquartered in Middletown, NY, is one of the largest PPO networks in the country representing more than seven million lives. Their list of clients includes multi-state companies, Fortune 500 companies, federal organizations, and regional employers. NPPN providers include Memorial Sloan-Kettering Cancer Center, North Shore Health Systems in New York, Quest Diagnostics and Brown and Toland in San Francisco.

PCA, located in Atlanta, GA, is a national network of healthcare providers representing over a million lives. Their panel of directly contracted providers includes independent physicians, medical group practices, specialty facilities, acute care hospitals, and ancillary medical providers. PCA has relationships with over 300 payors and 12,000 employers nationwide. Payors include Taft Hartley Funds, Self Funded Groups, Insurance Companies, Third Party Administrators, and HMOs.

SIEBA, LTD, located in Endicott, NY, links the delivery of services to the employer community in the Northeast Region of the US. SIEBA's focus is providing unparalleled third party administrative services for employee benefits in both public and private sectors in the Northeast.

Established in 1981, RMSCO is now one of the largest multi-line Third-Party Administrators in the Northeast. RMSCO, headquartered in Liverpool, NY provides services to over 200 clients representing over 200,000 individuals in all 50 states.

"Precision Therapeutics is pleased to add these organizations to our growing list of payor organizations under contract. Contracting with these leading organizations expands the number of covered lives, thus allowing our technology to be available to more patients and allowing for faster reimbursement of claims," said Precision CEO Sean McDonald.

About Precision Therapeutics

Precision Therapeutics is a diagnostics services company dedicated to providing physicians, patients, and payors with information to personalize cancer treatment. Precision's ChemoFx(R) test, based on a proprietary live tumor cell-based platform, measures an individual patient's tumor sensitivity and resistance to a clinically relevant range of therapeutic alternatives under consideration by the physician. Since introduction, over 5,000 ChemoFx tests have been performed commercially in over 30 different types of solid tumors. For more information visit http://www.precisiontherapeutics.com, call 800-547-6165 or email info@ptilabs.com.


'/>"/>
SOURCE Precision Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Precision Optics Corporation Announces Fourth Quarter and Year End Results With Highest Revenues in Six Years
2. Varian Medical Systems to Unveil RapidArc(TM) Volumetric Arc Therapy and Other Products Designed to Speed Delivery of Precision Radiotherapy and Brachytherapy
3. New Generation Xcelodose(R)S Precision Drug Powder Micro-filling System Offers 50% Increased Throughput
4. Precision Optics Corporation Announces First Quarter Results and Receipt of Significant New Order
5. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Agree in Principle to Amend Merger Agreement to Reduce Consideration by 15%
6. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Mutually Terminate Merger Agreement; Oracle Healthcare Acquisition Corp. Cancels Special Meeting
7. Prime Therapeutics Receives TIPPS Certification
8. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
9. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
10. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
11. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... ... announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for Input to ... Medical Informatics . , Results of the comparative usability study demonstrate that a ...
(Date:12/8/2016)... ... 2016 , ... With the increasing demand for dental implants, the National Association ... to inform dentists and patients about the safety issues related to dental restorations. According ... the U.S. is projected to reach $6.4 billion in 2018 with more than 30 ...
(Date:12/8/2016)... ... 08, 2016 , ... Launching of the ... Instance Manager architecture, meeting the needs of multichannel growth and doubling the ... auto-dialing system without agents, Presence Robodialer, provides greater operational capacity, administrative flexibility ...
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) 863, signed into ... claim in 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th ... According to the study, medical payments per claim in California decreased 4 percent in ...
(Date:12/8/2016)... Rock, AR (PRWEB) , ... December 08, 2016 ... ... providing insurance and financial planning services from offices headquartered in Little Rock, has ... Food Pantry. , According to the National Foundation to End Senior Hunger, Arkansas ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 8, 2016 KEY FINDINGS ... of the market in 2016 and is expected to ... attributed to a large number of surgical procedures that ... largest share in the patient temperature management market.) Patient ... reducing loss of blood during surgeries, lowering the risks ...
(Date:12/8/2016)... Research and Markets has announced the addition of the ... Application, Usability - Forecast to 2025" report to their offering. ... , , ... grow at a CAGR of around 3.2% from 2015 to 2025. ... advancements in extracellular microelectrode arrays and intracellular microelectrodes, research in left-to-right ...
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
Breaking Medicine Technology: